MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
2.060
-0.140
-6.36%
Opening 12:16 05/15 EDT
OPEN
2.150
PREV CLOSE
2.200
HIGH
2.160
LOW
2.014
VOLUME
155.37K
TURNOVER
--
52 WEEK HIGH
28.61
52 WEEK LOW
1.790
MARKET CAP
10.99M
P/E (TTM)
-0.0725
1D
5D
1M
3M
1Y
5Y
1D
Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate
Benzinga · 6h ago
Moleculin Biotech Q1 net loss widens as R&D costs rise
Reuters · 6h ago
Moleculin Biotech GAAP EPS of -$3.54 misses by $2.08
Seeking Alpha · 7h ago
Moleculin reports 40% blinded remission rate in pivotal MIRACLE AML trial
PUBT · 7h ago
*Moleculin Biotech: Runway to Support Planned Operations Into 3Q 2026 >MBRX
Dow Jones · 7h ago
MOLECULIN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE ON PIVOTAL MIRACLE TRIAL
Reuters · 7h ago
*Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX
Dow Jones · 7h ago
Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress and Safety Profile Support Unchanged $22 Price Target
TipRanks · 9h ago
More
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Webull offers Moleculin Biotech Inc stock information, including NASDAQ: MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.